Lilly wins round in Amylin scrap; Seattle Genetics takes co-develop option on ADC program; Protein could repair damaged hearts;

@FierceBiotech: What's in a (drug) name? Article | Follow @FierceBiotech

@JohnCFierce: Still early days on the Ph2 Vertex program. CFF CEO talks about "important new information about the potential to address the basic defect." | Follow @JohnCFierce

> Eli Lilly has won the latest round in its bitter court fight with longtime partner Amylin. Report

> Seattle Genetics has exercised an option to co-develop a second antibody-drug conjugate under its ADC collaboration agreement with Agensys. Seattle Genetics release

> Assay Depot, which has developed an automated process for hiring a CRO, has raised $1.7 million. Report

> Linda Powers, who runs Toucan Capital, has taken the helm at Northwest Biotherapeutics, an OTC biotech where she has been both chairwoman and financial backer. Northwest release

Pharma News

@FiercePharma: Oncologists lament growing drug shortages. Report | Follow @FiercePharma

> FDA tightens up use of high-dose Zocor. Report

> Pfizer to suspend common chicken drug on arsenic concerns. Story

> Court lifts restrictions on Lilly diabetes reps. Item

> Pharma faces bigger hurdles in Europe. Article

Vaccine News

> Adult vaccines cut down on healthcare costs. Article

> UCFS researchers unveil promising glioblastoma vaccine data. Report

> Vaccine makers cut prices for developing countries. Story

> J&J, GSK team on malaria vaccine. Article

> Vaxart starts Ph1 oral vax trial. Item

Pharma Manufacturing News

> Novartis leans on CMOs for ops gains. Article

> HP primed for large-scale track/trace. Report

> Disposables maker goes solar, targeting energy costs. Story

> Glass chips prompt another American Regent recall. Item

> India yanks license of uncooperative Chinese supplier. News

> Sun, Max RFID pilot advances. Report

And Finally...Researchers at UC London say that the protein thymosin Beta 4 appears to regenerate dormant cells in the hearts of adult patients, promising a new treatment for heart attack victims. Story

Suggested Articles

The project is built on the AlivaMab Mouse platform that is already widely used by in-house R&D teams at large biopharma companies.

The takeover centers on a near-approval anti-CGRP antibody that could address Lundbeck’s need for near-term revenue drivers.

As the White House continues its push for the benefits of "right to try," the first CRO associated with the law has come onto the stage.